Latest Healthcare News

Enlitic reported a 5.8% revenue increase in Q1 CY25, strengthened its collaboration with GE HealthCare, and accelerated integration of Laitek, positioning itself for operational cashflow break-even by the end of 2025.

D3 Energy’s latest quarterly report reveals a promising new helium production province at its ER315 permit, alongside expanded exploration permits and preparations for a key Production Right application.

Oakridge International Limited reported strong operational and financial progress for Q1 2025, highlighting increased trading income, positive cash flow, and a robust sales pipeline in healthcare IoT technology despite ongoing legal discussions.

Clarity Pharmaceuticals reports a robust cash position and strategic refocus on its lead prostate cancer asset, Cu-SAR-bisPSMA, supported by multiple FDA Fast Track designations and advancing clinical trials.

Imagion Biosystems has progressed its MagSense HER2 breast cancer imaging agent towards a pivotal Investigational New Drug application with the FDA, backed by a solid funding runway exceeding 13 quarters.

InteliCare Holdings has secured a new commercial trial with mecwacare and advanced deployments at Hardi Aged Care sites, underpinning growth in its AI-driven aged care platform amid regulatory changes.

TrivarX has launched a pivotal mental health clinical trial in partnership with the US Department of Veterans Affairs, leveraging its innovative ECG-based technology to screen for major depressive episodes. The company also secured $2.25 million in funding, positioning it for regulatory milestones ahead.

IMEXHS Limited reported modest revenue growth and a 16% increase in ARR in Q1 FY25, alongside the commercial rollout of its Aquila+ radiology platform and a $2.5 million capital raising to fuel expansion.

Mesoblast has commercially launched Ryoncil in the US for pediatric acute GVHD, backed by a strong cash position and advancing multiple cell therapy programs.

Genetic Signatures Ltd reported a robust 71% jump in quarterly sales to $2.9 million, fueled by strong respiratory testing demand in Australia and key US commercial contracts. The company is advancing its automation and instrument customisation strategy to streamline molecular diagnostics offerings.

MedAdvisor Limited reports a steep decline in 3Q FY25 revenue, driven by US market challenges, while accelerating cost-cutting and reaffirming full-year guidance.

Constellation Technologies Limited reports sustained sales growth and positive cash flow in Q3 2025, driven by its Callisto Food Safety & Compliance system and strategic market expansion.